Close Menu
  • Home
  • News
  • Politics
  • Health
  • Business
  • Education
  • Opinion
  • Lifestyle
  • Entertainment
Facebook X (Twitter) Instagram
The Meridian Spy
  • Home
  • News
  • Politics
  • Health
  • Business
  • Education
  • Opinion
  • Lifestyle
  • Entertainment
The Meridian Spy
Home»Health»WHO Approves Dexamethasone Drug For Treatment Of Critically Ill COVID-19 Patients
Health

WHO Approves Dexamethasone Drug For Treatment Of Critically Ill COVID-19 Patients

Kennedy IgweBy Kennedy IgweJune 23, 2020No Comments3 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email
Share
    

Share!

  • Share
  • Tweet

The World Health Organisation (WHO) has approved the use of the drug “dexamethasone” for the treatment of critically-ill coronavirus patients.

This was made known by the WHO Director-General, Tedros Ghebreyesus at a press briefing on Monday.

MERIDIAN SPY reports days ago the widely-used steroid called “dexamethasone”, normally used to reduce inflammation in other diseases such as arthritis, reduced death rates by around a third among the most severely ill of COVID-19 patients admitted to hospital.

It became the first drug shown to be able to save lives among COVID-19 patients in what scientists said is a “major breakthrough” in the pandemic.

A team of medical researchers from Oxford University, led by Martin Landry, said the drug costs £5 per patient and is available worldwide.

Ghebreyesus, speaking on the use of dexamethasone, called for increased production and distribution, but emphasised that there is no evidence that the drug works for patients with mild symptoms.

“Although the data are still preliminary, the recent finding that the steroid dexamethasone has life-saving potential for critically ill COVID-19 patients gave us a much-needed reason to celebrate,” he said.

“The next challenge is to increase production and rapidly and equitably distribute dexamethasone worldwide, focusing on where it is needed most.

“Demand has already surged, following the UK trial results showing dexamethasone’s clear benefit. Fortunately, this is an inexpensive medicine and there are many dexamethasone manufacturers worldwide, who we are confident can accelerate production.

READ ALSO  Abia Government Dissolves Enyimba Management, Technical Crew Over Poor Performance

“Guided by solidarity, countries must work together to ensure supplies are prioritised for countries where there are large numbers of critically ill patients, and that supplies remain available to treat other diseases for which it is needed.

“Transparency and constant monitoring will be key to ensuring needs dictate supplies, rather than means. It is also important to check that suppliers can guarantee quality, as there is a high risk of substandard or falsified products entering the market.

“WHO emphasises that dexamethasone should only be used for patients with severe or critical disease, under close clinical supervision.

“There is no evidence this drug works for patients with mild disease or as a preventative measure, and it could cause harm.”

The Nigeria Centre for Disease Control (NCDC), MERIDIAN SPY reports, had before the approval said it was aware of recent outcomes from a UK-Government funded clinical trial of the drug but warned that it has not validated or approved the drug for treatment of COVID-19, nor has the WHO.

Related posts:

  1. NAFDAC To Continue Clinical Trial Of Hydroxychloroquine Despite WHO’s Decision
  2. COVID-19: WHO Suspends Hydroxychloroquine Trial
  3. Use Of “Dexamethasone” For COVID-19 Treatment Not Validated By WHO – NCDC Warns
  4. BREAKING: NCDC Storms Bonny Over Strange Deaths Of 11 In Two Weeks
COVID-19 Pandemic Dexamethasone Meridian Spy Tedros Adhanom Ghebreyesus WHO
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Kennedy Igwe

Related Posts

Wike Approves Promotion of 7,714 FCT Civil Servants, 4,220 Teachers Benefit

November 17, 2026

Abia Government Dissolves Enyimba Management, Technical Crew Over Poor Performance

November 17, 2026

Mustapha Abdullahi Advances Nigeria’s Global Bioenergy Ambition, Seals GBEP Membership in Rome

November 16, 2026
Search
Recent Posts
  • Wike Approves Promotion of 7,714 FCT Civil Servants, 4,220 Teachers Benefit
  • Abia Government Dissolves Enyimba Management, Technical Crew Over Poor Performance
  • Mustapha Abdullahi Advances Nigeria’s Global Bioenergy Ambition, Seals GBEP Membership in Rome
  • Igbokoda Crash: NAF Recovers Black Box, Holds Memorial November 26
  • Imposing Tinubu in 2027 Will Trigger Crisis — Ex-APC Spokesman
  • NDC Will Resist Attacks With Equal Force – Aisha Yesufu
  • Why I Lied About Having Cancer – Blessing CEO 
  • Why I Accepted Man United Job – Pochettino
  • NITDA Unveils ₦3bn Builders Festival for Nigerian Startups
  • Nafiu Bala Begged For N50k Fare To Attend Meetings, He Now Rides In Bulletproof SUVs, Ralph Nwosu Alleges
  • 67% Of Prosecutors, 52% Of Judges Collect Bribes – Report
  • ECN DG Engages Global Energy Stakeholders At COP31 In Türkiye
  • COP31 Breaks Attendance Record With 92,934 Registered Participants
  • Shettima Asks Ondo Residents To Deliver 1.2m Votes For Tinubu In 2027
  • Most Christians We’ve Engaged Are Okay With Muslim-Muslim Ticket – APC Chairman 
Categories
  • Business
  • Crime
  • Education
  • Entertainment
  • Environment
  • Foreign
  • Health
  • Investigations
  • Labour
  • Lifestyle
  • Metro
  • News
  • Opinion
  • Politics
  • Security
  • Sport
  • Technology
  • World news
Access Bank DiamondXtra Season 16 Rewards
  • About us
  • Contact Us
  • News
  • Politics
  • Health
© 2026 All Right Reserved. Designed by Techjuno

Type above and press Enter to search. Press Esc to cancel.